Introdução: Poucos estudos avaliaram o valor prognóstico em longo prazo da presença, extensão e gravidade da doença arterial coronária (DAC) detectada pela angiotomografia computadorizada de artérias coronárias (TCcor). Métodos: Todos os pacientes consecutivos sem DAC prévia que realizaram TCcor para avaliar DAC foram incluídos. Os resultados da TCcor foram classificados como normal, DAC não-obstrutiva (estenose < 50%), ou obstrutiva (>= 50%). Além disso, com base no número de segmentos com a doença, a DAC foi classificada como não-extensa (<= 4 segmentos) ou extensa (> 4 segmentos). Os pacientes foram acompanhados para o desfecho primário de eventos cardiovasculares (CV) incluindo morte ou infarto do miocárdio (IAM) e um desfecho secundário dos eventos cardiovasculares adversos maiores, constituído por morte CV, IAM ou revascularização coronária tardia (> 90 dias). Resultados: Entre 3242 pacientes acompanhados por uma média de 3,6 ± 1,8 anos, ocorreram 92 (2,8%) eventos primários e 195 (6,0%) apresentaram o desfecho secundário. Em uma análise multivariada, foram associados com aumento de eventos a presença de DAC extensa não-obstrutiva (hazard ratio (HR): 3.1, intervalo de confiança de 95% (IC): 1,5-6,5); não-extensa obstrutiva (HR: 3,0, IC 95%: 1,3 - 7,0) e DAC obstrutiva extensa (HR: 3,9, IC 95%: 2,1-7,2), enquanto os não-extensiva CAD não-obstrutiva não esteve associada a eventos (HR: 1,3, IC 95%: 0,6-2,4). A adição da extensão da placa a um modelo que incluía probabilidade clínica de DAC, assim como a presença e gravidade de DAC resultou na melhoria da predição de eventos CV. Conclusão: Entre os pacientes com DAC não obstrutiva, aqueles com mais de 4 segmentos com doença apresentaram uma maior taxa de CV morte ou MI, comparáveis aos que têm doença obstrutiva com <= 4 segmentos. Mesmo entre os pacientes com DAC obstrutiva, maior extensão de placa esteve associado com maior taxa de eventos. Estes resultados sugerem que, independentemente da presença de estenose, a extensão da placa não-obstrutiva reforça a avaliação de risco além dos dados clínicos e outros achados TCcor / Introduction: There is limited prior data on the long-term prognostic value of the presence, extent and severity of both non-obstructive and obstructive CAD detected by coronary computed tomography angiography (CCTA). Methods: All consecutive patients without prior CAD referred for CCTA to evaluate for CAD were included. CCTA findings were classified as normal, non-obstructive (< 50% stenosis) or obstructive (>= 50%) disease. Additionally, based on the number of segments with disease, extent of CAD was classified as non-extensive (<=4 segments) or extensive (> 4 segments). Patients were followed for a primary endpoint of cardiovascular (CV) death or myocardial infarction (MI) and a secondary endpoint of major adverse cardiovascular events (MACE) consisting of CV death, MI or late coronary revascularization (> 90 days). Results: Among 3242 patients followed for a mean of 3.6±1.8 years, 92 (2.8%) patients who experienced the primary endpoints and 195 (6.0%) experienced the secondary endpoint. In a multivariable analysis, the presence of extensive non-obstructive CAD (hazard ratio (HR): 3.1, 95% confidence interval (CI): 1.5 - 6.5); non-extensive obstructive (HR: 3.0, 95%CI: 1.3 - 7.0) and extensive obstructive CAD (HR: 3.9, 95%CI: 2.1 - 7.2) were associated with increase in the rate of the primary endpoint, while non-extensive non-obstructive CAD was not (HR: 1.3, 95%CI: 0.6 - 2.4). The addition of the extent of plaque to a model, which included clinical probability of CAD as well as the presence and severity of CAD, resulted in improved prediction of all endpoints. Conclusion: Among patients with non-obstructive CAD, those with more than 4 segments with disease experienced a higher rate CV death or MI, comparable to those who have obstructive disease with <= 4 diseased segments. Even among patients with obstructive CAD, greater extent of non-obstructive plaque was associated with higher event rate. These findings suggest that regardless of whether stenosis is present or absent, the extent of non-obstructive plaque enhances risk assessment beyond clinical data and other CCTA findings

O principal objetivo desse trabalho é introduzir um modelo geral bayesiano Weibull hierárquico para dados censurados que estima a função de confiabilidade de cada componente para sistemas de confiabilidade coerentes. São introduzidos formas de estimação mais sólidas, sem a inserção de estimativas médias nas funções de confiabilidade (estimador plug-in). Através desse modelo, são expostos e solucionados exemplos na área de confiabilidade como sistemas em série, sistemas em paralelo, sistemas k-de-n, sistemas bridge e um estudo clínico com dados censurados intervalares. As soluções consideram que as componentes tem diferentes distribuições, e nesse caso, o sistema bridge ainda não havia solução na literatura. O modelo construído é geral e pode ser utilizado para qualquer sistema coerente e não apenas para dados da área de confiabilidade, como também na área de sobrevivência, dentre outros. Diversas simulações com componentes com diferentes proporções de censura, distintas médias, três tipos de distribuições e tamanhos de amostra foram feitas em todos os sistemas para avaliar a eficácia do modelo. / The main purpose of this work is to introduce a general bayesian Weibull hierarchical model for censored data which estimates each reliability components function from coherent systems. Its introduced estimation procedures which do not consider plug-in estimators. Also, its exposed and solved with this model examples in reliability area such as series systems, parallel systems, k-out-of-n systems, bridge systems and a clinical study with interval censoring data. The problem of bridge system hadnt a solution before for the case of each component with different distribution. Actually, this model is general and can be used to analyse any kind of coherent system and censored data, not only reliability ones, but also survival data and others. Several components simulations with different censored proportions, distinct means, three kinds of distributions and sample size were made in all systems to evaluate model efficiency.

O principal objetivo desse trabalho é introduzir um modelo geral bayesiano Weibull hierárquico para dados censurados que estima a função de confiabilidade de cada componente para sistemas de confiabilidade coerentes. São introduzidos formas de estimação mais sólidas, sem a inserção de estimativas médias nas funções de confiabilidade (estimador plug-in). Através desse modelo, são expostos e solucionados exemplos na área de confiabilidade como sistemas em série, sistemas em paralelo, sistemas k-de-n, sistemas bridge e um estudo clínico com dados censurados intervalares. As soluções consideram que as componentes tem diferentes distribuições, e nesse caso, o sistema bridge ainda não havia solução na literatura. O modelo construído é geral e pode ser utilizado para qualquer sistema coerente e não apenas para dados da área de confiabilidade, como também na área de sobrevivência, dentre outros. Diversas simulações com componentes com diferentes proporções de censura, distintas médias, três tipos de distribuições e tamanhos de amostra foram feitas em todos os sistemas para avaliar a eficácia do modelo. / The main purpose of this work is to introduce a general bayesian Weibull hierarchical model for censored data which estimates each reliability components function from coherent systems. Its introduced estimation procedures which do not consider plug-in estimators. Also, its exposed and solved with this model examples in reliability area such as series systems, parallel systems, k-out-of-n systems, bridge systems and a clinical study with interval censoring data. The problem of bridge system hadnt a solution before for the case of each component with different distribution. Actually, this model is general and can be used to analyse any kind of coherent system and censored data, not only reliability ones, but also survival data and others. Several components simulations with different censored proportions, distinct means, three kinds of distributions and sample size were made in all systems to evaluate model efficiency.

Introdução: Poucos estudos avaliaram o valor prognóstico em longo prazo da presença, extensão e gravidade da doença arterial coronária (DAC) detectada pela angiotomografia computadorizada de artérias coronárias (TCcor). Métodos: Todos os pacientes consecutivos sem DAC prévia que realizaram TCcor para avaliar DAC foram incluídos. Os resultados da TCcor foram classificados como normal, DAC não-obstrutiva (estenose < 50%), ou obstrutiva (>= 50%). Além disso, com base no número de segmentos com a doença, a DAC foi classificada como não-extensa (<= 4 segmentos) ou extensa (> 4 segmentos). Os pacientes foram acompanhados para o desfecho primário de eventos cardiovasculares (CV) incluindo morte ou infarto do miocárdio (IAM) e um desfecho secundário dos eventos cardiovasculares adversos maiores, constituído por morte CV, IAM ou revascularização coronária tardia (> 90 dias). Resultados: Entre 3242 pacientes acompanhados por uma média de 3,6 ± 1,8 anos, ocorreram 92 (2,8%) eventos primários e 195 (6,0%) apresentaram o desfecho secundário. Em uma análise multivariada, foram associados com aumento de eventos a presença de DAC extensa não-obstrutiva (hazard ratio (HR): 3.1, intervalo de confiança de 95% (IC): 1,5-6,5); não-extensa obstrutiva (HR: 3,0, IC 95%: 1,3 - 7,0) e DAC obstrutiva extensa (HR: 3,9, IC 95%: 2,1-7,2), enquanto os não-extensiva CAD não-obstrutiva não esteve associada a eventos (HR: 1,3, IC 95%: 0,6-2,4). A adição da extensão da placa a um modelo que incluía probabilidade clínica de DAC, assim como a presença e gravidade de DAC resultou na melhoria da predição de eventos CV. Conclusão: Entre os pacientes com DAC não obstrutiva, aqueles com mais de 4 segmentos com doença apresentaram uma maior taxa de CV morte ou MI, comparáveis aos que têm doença obstrutiva com <= 4 segmentos. Mesmo entre os pacientes com DAC obstrutiva, maior extensão de placa esteve associado com maior taxa de eventos. Estes resultados sugerem que, independentemente da presença de estenose, a extensão da placa não-obstrutiva reforça a avaliação de risco além dos dados clínicos e outros achados TCcor / Introduction: There is limited prior data on the long-term prognostic value of the presence, extent and severity of both non-obstructive and obstructive CAD detected by coronary computed tomography angiography (CCTA). Methods: All consecutive patients without prior CAD referred for CCTA to evaluate for CAD were included. CCTA findings were classified as normal, non-obstructive (< 50% stenosis) or obstructive (>= 50%) disease. Additionally, based on the number of segments with disease, extent of CAD was classified as non-extensive (<=4 segments) or extensive (> 4 segments). Patients were followed for a primary endpoint of cardiovascular (CV) death or myocardial infarction (MI) and a secondary endpoint of major adverse cardiovascular events (MACE) consisting of CV death, MI or late coronary revascularization (> 90 days). Results: Among 3242 patients followed for a mean of 3.6±1.8 years, 92 (2.8%) patients who experienced the primary endpoints and 195 (6.0%) experienced the secondary endpoint. In a multivariable analysis, the presence of extensive non-obstructive CAD (hazard ratio (HR): 3.1, 95% confidence interval (CI): 1.5 - 6.5); non-extensive obstructive (HR: 3.0, 95%CI: 1.3 - 7.0) and extensive obstructive CAD (HR: 3.9, 95%CI: 2.1 - 7.2) were associated with increase in the rate of the primary endpoint, while non-extensive non-obstructive CAD was not (HR: 1.3, 95%CI: 0.6 - 2.4). The addition of the extent of plaque to a model, which included clinical probability of CAD as well as the presence and severity of CAD, resulted in improved prediction of all endpoints. Conclusion: Among patients with non-obstructive CAD, those with more than 4 segments with disease experienced a higher rate CV death or MI, comparable to those who have obstructive disease with <= 4 diseased segments. Even among patients with obstructive CAD, greater extent of non-obstructive plaque was associated with higher event rate. These findings suggest that regardless of whether stenosis is present or absent, the extent of non-obstructive plaque enhances risk assessment beyond clinical data and other CCTA findings

Indiana University-Purdue University Indianapolis (IUPUI) / In medical research, data analysis often requires complex statistical methods where no closed-form solutions are available. Under such circumstances, Monte Carlo (MC) methods have found many applications. In this dissertation, we proposed several novel statistical models where MC methods are utilized. For the first part, we focused on semicompeting risks data in which a non-terminal event was subject to dependent censoring by a terminal event. Based on an illness-death multistate survival model, we proposed flexible random effects models. Further, we extended our model to the setting of joint modeling where both semicompeting risks data and repeated marker data are simultaneously analyzed. Since the proposed methods involve high-dimensional integrations, Bayesian Monte Carlo Markov Chain (MCMC) methods were utilized for estimation. The use of Bayesian methods also facilitates the prediction of individual patient outcomes. The proposed methods were demonstrated in both simulation and case studies. For the second part, we focused on re-randomization test, which is a nonparametric method that makes inferences solely based on the randomization procedure used in clinical trials. With this type of inference, Monte Carlo method is often used for generating null distributions on the treatment difference. However, an issue was recently discovered when subjects in a clinical trial were randomized with unbalanced treatment allocation to two treatments according to the minimization algorithm, a randomization procedure frequently used in practice. The null distribution of the re-randomization test statistics was found not to be centered at zero, which comprised power of the test. In this dissertation, we investigated the property of the re-randomization test and proposed a weighted re-randomization method to overcome this issue. The proposed method was demonstrated through extensive simulation studies.

Indiana University-Purdue University Indianapolis (IUPUI) / Epidemiologic and clinical studies routinely collect longitudinal measures of multiple outcomes. These longitudinal outcomes can be used to establish the temporal order of relevant biological processes and their association with the onset of clinical symptoms. In the first part of this thesis, we proposed to use bivariate change point models for two longitudinal outcomes with a focus on estimating the correlation between the two change points. We adopted a Bayesian approach for parameter estimation and inference. In the second part, we considered the situation when time-to-event outcome is also collected along with multiple longitudinal biomarkers measured until the occurrence of the event or censoring. Joint models for longitudinal and time-to-event data can be used to estimate the association between the characteristics of the longitudinal measures over time and survival time. We developed a maximum-likelihood method to joint model multiple longitudinal biomarkers and a time-to-event outcome. In addition, we focused on predicting conditional survival probabilities and evaluating the predictive accuracy of multiple longitudinal biomarkers in the joint modeling framework. We assessed the performance of the proposed methods in simulation studies and applied the new methods to data sets from two cohort studies. / National Institutes of Health (NIH) Grants R01 AG019181, R24 MH080827, P30 AG10133, R01 AG09956.

Indiana University-Purdue University Indianapolis (IUPUI) / Phytoestrogens that abound in soy products, legumes, and chickpeas can induce biologic responses in animals and humans due to structural similarity to 17β-estradiol. Although experimental studies suggest that phytoestrogen intake may alter the risk of cancer and cardiovascular disease, few epidemiologic studies have investigated this research question. This dissertation investigated the associations of intake of total and individual phytoestrogens and their urinary biomarkers with these chronic conditions using data previously collected from two US national cohort studies (NHANES and PLCO). Utilizing NHANES data with urinary phytoestrogen concentrations and follow-up mortality, Cox proportional hazards regression (HR; 95% CI) were performed to evaluate the association between total cancer, cardiovascular disease, and all-cause mortality and urinary phytoestrogens. After adjustment for confounders, it was found that higher concentrations of lignans were associated with a reduced risk of death from cardiovascular disease (0.48; 0.24-0.97), whereas higher concentrations of isoflavones (2.14; 1.03-4.47) and daidzein (2.05; 1.02-4.11) were associated with an increased risk. A reduction in all-cause mortality was observed for elevated concentrations of lignans (0.65; 0.43-0.96) and enterolactone (0.65; 0.44-0.97). Utilizing PLCO data and dietary phytoestrogens, Cox proportional hazards regression examined the associations between dietary phytoestrogens and the risk of prostate cancer incidence. After adjustment for confounders, a positive association was found between dietary intake of isoflavones (1.58; 1.11-2.24), genistein (1.42; 1.02-1.98), daidzein (1.62; 1.13-2.32), and glycitein (1.53; 1.09-2.15) and the risk of advanced prostate cancer. Conversely, an inverse association existed between dietary intake of genistein and the risk of non-advanced prostate cancer (0.88; 0.78-0.99) and total prostate cancer (0.90; 0.81-1.00). C-reactive protein (CRP) concentration levels rise in response to inflammation and higher levels are a risk factor for some cancers and cardiovascular disease reported in epidemiologic studies. Logistic regression performed on NHANES data evaluated the association between CRP and urinary phytoestrogen concentrations. Higher concentrations of total and individual phytoestrogens were associated with lower concentrations of CRP. In summary, dietary intake of some phytoestrogens significantly modulates prostate cancer risk and cardiovascular disease mortality. It is possible that these associations may be in part mediated through the influence of phytoestrogen intake on circulating levels of C-reactive protein.

Introdução: Existem dados suficientes disponíveis demonstrando a importância da quimiocina CXCL12 e seu receptor CXCR4 na progressão tumoral e angiogênese dos gliomas. O CXCR4 é regulado positivamente pelo HIF1alfa. Recentemente um novo receptor com maior afinidade à CXCL12 foi identificado, o receptor órfão RDC1, agora denominado CXCR7. O objetivo deste estudo é investigar a expressão de mRNA CXCR7 em tecidos astrocitomas difusos e avaliar suas interações com expressão CXCR4 e HIF1alfa, bem como analisar sua relação com mutação do IDH1. Métodos: A expressão do CXCR7, CXCR4, IDH1 e HIF1alfa foram avaliadas por PCR quantitativo em tempo real (qRT-PCR) em 129 amostras congeladas de astrocitomas (25 astrocitoma difuso - AGII, 18 de astrocitoma anaplásico - AGIII e 86 glioblastoma - GBM) e 22 amostras de tecido cerebral não neoplásico (NN) obtidos de cirurgia de epilepsia. A mutação do IDH1 previamente determinada foi analisada em relação aos níveis de expressões de mRNA do CXCR7, CXCR4 e HIF1alfa, combinado com os parâmetros clínico-patológicos e sobrevida global. Adicionalmente, a expressão proteica do CXCR7 foi analisada por imuno-histoquímica em astrocitomas de diferentes graus e em linhagem celular de glioma (U87MG) por microscopia confocal. Resultados: Houve diferença significativa nos níveis de expressão dos genes estudados entre astrocitomas e NN (p < 0,001). Na análise da expressão gênica associada nos AGII não se observou correlação entre os níveis de expressão de CXCR7/HIF1alfa (p = 0,548); observou-se correlação significativa entre CXCR7/IDH1 (p < 0,001) e CXCR7/CXCR4 (p = 0,042). Nos GBM houve correlação significativa entre CXCR7/CXCR4 (p = 0,002), CXCR7/IDH1 (p < 0,001) e CXCR7/HIF1alfa (p = 0,008). Hiperexpressão do HIF1alfa foi associado com maior expressão do CXCR7 e CXCR4 (p = 0,001), enquanto a presença de IDH1 mutado foi associada a menor expressão de mRNA do CXCR7 e CXCR4 (p = 0,009). A expressão proteica de CXCR7 foi identificada em todas as amostras estudadas, e aumentou com malignidade. A proteína CXCR7, na linha celular U87MG, foi localizada principalmente na membrana celular. Conclusão: O CXCR7 é um gene diferencialmente expresso em astrocitomas difusamente infiltrativos em relação tecido cerebral não neoplásico. O nível de expressão do CXCR7 correlacionou-se significativamente com os níveis de expressão do CXCR4 e IDH1 nos AGII e com CXCR4, IDH1 e HIF-1alfa nos GBM. O nível de expressão elevado do CXCR7 e CXCR4 correlacionou-se com nível elevado de expressão de HIF-1a, enquanto a presença da mutação do IDH1 associou-se a níveis reduzidos de CXCR7 e CXCR4. Não se observou associação significativa entre os níveis de expressão de CXCR7 e CXCR4 com os dados de sobrevida / Introduction: There is abundant evidence showing that chemokine CXCL12 and its receptor CXCR4 are involved in glioma progression and angiogenesis. CXCR4 is upregulated by HIF1alfa. The CXCR7, a recent additional receptor for CXCL12 with higher affinity than CXCR4 has raised key issues on glioma cell migration. The aim of this study is to investigate the CXCR7 mRNA expression in diffuse astrocytoma tissues and to evaluate its interactions with CXCR4 and HIF1alfa expression and IDH1 mutation. Methods: CXCR7, CXCR4, IDH1 and HIF1alfa expressions were evaluated by quantitative real-time PCR (qRT-PCR) in 129 frozen samples of astrocytoma (25 diffuse astrocytomas - AGII, 18 anaplastic astrocytomas - AGIII and 86 glioblastomas - GBM) and 22 samples of non-neoplastic tissue cerebral (NN) from epilepsy surgery. IDH1 mutation status was analyzed with CXCR7, CXCR4 e HIF1alfa mRNA expressions, matched with clinicopathological parameters and overall survival time. Furthermore, CXCR7 protein expression was analyzed by immunohistochemistry in different grades of astrocytoma and in glioma cell line (U87MG) by confocal microscopy. Results: There was significant difference in the expression levels of the genes studied between astrocytomas and NN (p < 0.001). The analysis of associated gene expressions in AGII showed no significant correlation between CXCR7/HIF1alfa (p = 0.548); there was significant correlation between CXCR7/CXCR4 (p = 0.042) and CXCR7/IDH1 (p = 0.008). In GBM, there were significant correlations between CXCR7/CXCR4 (p = 0.002), CXCR7/IDH1 (p < 0.001) and CXCR7/HIF1alfa (p = 0.008). HIF1alfa overexpression was associated with higher expressions of CXCR7 and CXCR4 (p = 0.001), while presence of IDH1 mutation was associated with lower CXCR7 and CXCR4 mRNA expressions (p = 0.009). Protein expression was identified in all samples studied, and it increased with malignancy. CXCR7 protein, in U87MG cell line, was mainly localized in the cellular membrane. Conclusion: CXCR7 was overexpressed in astrocytoma of different grades of malignancy compared to non-neoplastic brain tissue. CXCR7 expression levels correlates with CXCR4 and IDH1 in AGII and CXCR4, IDH1 and HIF1alfa in GBM. Overexpression HIF1alfa was related with higher expressions of CXCR7 and CXCR4, otherwise presence of IDH1 mutation related with lower expression of both genes. Protein expression level was associated with the degree of malignancy. The results revealed no significant association between CXCR7 and CXCR4 expression and survival data

Introdução: Existem dados suficientes disponíveis demonstrando a importância da quimiocina CXCL12 e seu receptor CXCR4 na progressão tumoral e angiogênese dos gliomas. O CXCR4 é regulado positivamente pelo HIF1alfa. Recentemente um novo receptor com maior afinidade à CXCL12 foi identificado, o receptor órfão RDC1, agora denominado CXCR7. O objetivo deste estudo é investigar a expressão de mRNA CXCR7 em tecidos astrocitomas difusos e avaliar suas interações com expressão CXCR4 e HIF1alfa, bem como analisar sua relação com mutação do IDH1. Métodos: A expressão do CXCR7, CXCR4, IDH1 e HIF1alfa foram avaliadas por PCR quantitativo em tempo real (qRT-PCR) em 129 amostras congeladas de astrocitomas (25 astrocitoma difuso - AGII, 18 de astrocitoma anaplásico - AGIII e 86 glioblastoma - GBM) e 22 amostras de tecido cerebral não neoplásico (NN) obtidos de cirurgia de epilepsia. A mutação do IDH1 previamente determinada foi analisada em relação aos níveis de expressões de mRNA do CXCR7, CXCR4 e HIF1alfa, combinado com os parâmetros clínico-patológicos e sobrevida global. Adicionalmente, a expressão proteica do CXCR7 foi analisada por imuno-histoquímica em astrocitomas de diferentes graus e em linhagem celular de glioma (U87MG) por microscopia confocal. Resultados: Houve diferença significativa nos níveis de expressão dos genes estudados entre astrocitomas e NN (p < 0,001). Na análise da expressão gênica associada nos AGII não se observou correlação entre os níveis de expressão de CXCR7/HIF1alfa (p = 0,548); observou-se correlação significativa entre CXCR7/IDH1 (p < 0,001) e CXCR7/CXCR4 (p = 0,042). Nos GBM houve correlação significativa entre CXCR7/CXCR4 (p = 0,002), CXCR7/IDH1 (p < 0,001) e CXCR7/HIF1alfa (p = 0,008). Hiperexpressão do HIF1alfa foi associado com maior expressão do CXCR7 e CXCR4 (p = 0,001), enquanto a presença de IDH1 mutado foi associada a menor expressão de mRNA do CXCR7 e CXCR4 (p = 0,009). A expressão proteica de CXCR7 foi identificada em todas as amostras estudadas, e aumentou com malignidade. A proteína CXCR7, na linha celular U87MG, foi localizada principalmente na membrana celular. Conclusão: O CXCR7 é um gene diferencialmente expresso em astrocitomas difusamente infiltrativos em relação tecido cerebral não neoplásico. O nível de expressão do CXCR7 correlacionou-se significativamente com os níveis de expressão do CXCR4 e IDH1 nos AGII e com CXCR4, IDH1 e HIF-1alfa nos GBM. O nível de expressão elevado do CXCR7 e CXCR4 correlacionou-se com nível elevado de expressão de HIF-1a, enquanto a presença da mutação do IDH1 associou-se a níveis reduzidos de CXCR7 e CXCR4. Não se observou associação significativa entre os níveis de expressão de CXCR7 e CXCR4 com os dados de sobrevida / Introduction: There is abundant evidence showing that chemokine CXCL12 and its receptor CXCR4 are involved in glioma progression and angiogenesis. CXCR4 is upregulated by HIF1alfa. The CXCR7, a recent additional receptor for CXCL12 with higher affinity than CXCR4 has raised key issues on glioma cell migration. The aim of this study is to investigate the CXCR7 mRNA expression in diffuse astrocytoma tissues and to evaluate its interactions with CXCR4 and HIF1alfa expression and IDH1 mutation. Methods: CXCR7, CXCR4, IDH1 and HIF1alfa expressions were evaluated by quantitative real-time PCR (qRT-PCR) in 129 frozen samples of astrocytoma (25 diffuse astrocytomas - AGII, 18 anaplastic astrocytomas - AGIII and 86 glioblastomas - GBM) and 22 samples of non-neoplastic tissue cerebral (NN) from epilepsy surgery. IDH1 mutation status was analyzed with CXCR7, CXCR4 e HIF1alfa mRNA expressions, matched with clinicopathological parameters and overall survival time. Furthermore, CXCR7 protein expression was analyzed by immunohistochemistry in different grades of astrocytoma and in glioma cell line (U87MG) by confocal microscopy. Results: There was significant difference in the expression levels of the genes studied between astrocytomas and NN (p < 0.001). The analysis of associated gene expressions in AGII showed no significant correlation between CXCR7/HIF1alfa (p = 0.548); there was significant correlation between CXCR7/CXCR4 (p = 0.042) and CXCR7/IDH1 (p = 0.008). In GBM, there were significant correlations between CXCR7/CXCR4 (p = 0.002), CXCR7/IDH1 (p < 0.001) and CXCR7/HIF1alfa (p = 0.008). HIF1alfa overexpression was associated with higher expressions of CXCR7 and CXCR4 (p = 0.001), while presence of IDH1 mutation was associated with lower CXCR7 and CXCR4 mRNA expressions (p = 0.009). Protein expression was identified in all samples studied, and it increased with malignancy. CXCR7 protein, in U87MG cell line, was mainly localized in the cellular membrane. Conclusion: CXCR7 was overexpressed in astrocytoma of different grades of malignancy compared to non-neoplastic brain tissue. CXCR7 expression levels correlates with CXCR4 and IDH1 in AGII and CXCR4, IDH1 and HIF1alfa in GBM. Overexpression HIF1alfa was related with higher expressions of CXCR7 and CXCR4, otherwise presence of IDH1 mutation related with lower expression of both genes. Protein expression level was associated with the degree of malignancy. The results revealed no significant association between CXCR7 and CXCR4 expression and survival data

En fiabilité et en analyse de survie, les distributions qui ont une fonction de hasard unimodale ne sont pas nombreuses, qu'on peut citer: Gaussienne inverse ,log-normale, log-logistique, de Birnbaum-Saunders, de Weibull exponentielle et de Weibullgénéralisée. Dans cette thèse, nous développons les tests modifiés du Chi-deux pour ces distributions tout en comparant la distribution Gaussienne inverse avec les autres. Ensuite nousconstruisons le modèle AFT basé sur la distribution Gaussienne inverse et les systèmes redondants basés sur les distributions de fonction de hasard unimodale. / In reliability and survival analysis, distributions that have a unimodalor $\cap-$shape hazard rate function are not too many, they include: the inverse Gaussian,log-normal, log-logistic, Birnbaum-Saunders, exponential Weibull and power generalized Weibulldistributions. In this thesis, we develop the modified Chi-squared tests for these distributions,and we give a comparative study between the inverse Gaussian distribution and the otherdistributions, then we realize simulations. We also construct the AFT model based on the inverseGaussian distribution and redundant systems based on distributions having a unimodal hazard ratefunction.